[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100639304":3},{"organization":4,"armGroups":7,"interventions":15,"overallOfficials":21,"centralContacts":27,"locations":38,"responsibleParty":56,"collaborators":21,"id":60,"slug":61,"hasResults":62,"nctId":63,"briefTitle":64,"officialTitle":65,"acronym":66,"eligibilityCriteria":67,"healthyVolunteers":62,"sex":68,"minAge":69,"maxAge":70,"enrollmentInfo":71,"targetDuration":21,"studyType":74,"phases":75,"briefSummary":77,"conditions":78,"keywords":82,"overallStatus":88,"whyStopped":21,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":93,"completionDateStruct":94,"leadSponsor":96,"locationsCount":97},{"fullName":5,"class":6},"Hospital de Clínicas Dr. Manuel Quintela","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Phenotype-Guided Diagnostic and Therapeutic Strategy","EXPERIMENTAL","Participants will undergo a standardized invasive coronary assessment to identify functional and morphological mechanisms of angina with non-obstructive coronary arteries. Based on the identified phenotype, participants will receive individualized treatment including targeted pharmacological therapy, adapted cardiovascular rehabilitation, and psycho-emotional support when clinically indicated.",[13,14],"Procedure: Invasive Coronary Functional and Morphological Assessment","Drug: Pharmacological treatment will be individualized according to the invasive coronary phenotype identified. Treatment may include antianginal therapy, vasodilator therapy, endothelial function-targeted",[16,22],{"type":17,"name":18,"description":19,"armGroupLabels":20,"otherNames":21},"PROCEDURE","Invasive Coronary Functional and Morphological Assessment","Participants will undergo invasive coronary assessment including coronary physiology measurements, acetylcholine provocation testing, and optical coherence tomography to identify functional and morphological mechanisms of angina with non-obstructive coronary arteries.",[9],null,{"type":23,"name":24,"description":25,"armGroupLabels":26,"otherNames":21},"DRUG","Pharmacological treatment will be individualized according to the invasive coronary phenotype identified. Treatment may include antianginal therapy, vasodilator therapy, endothelial function-targeted","Pharmacological treatment will be individualized according to the invasive coronary phenotype identified. Treatment may include antianginal therapy, vasodilator therapy, endothelial function-targeted therapy, cardiovascular risk factor optimization, or revascularization evaluation when clinically indicated.",[9],[28,34],{"name":29,"role":30,"phone":31,"phoneExt":32,"email":33},"Rafael Mila, MD","CONTACT","+59824871515","9","r1000a@gmail.com",{"name":35,"role":30,"phone":36,"phoneExt":32,"email":37},"Victor Dayan, MD, PhD","+5989924871515","victordayan24@gmail.com",[39],{"facility":5,"status":21,"city":40,"state":41,"zip":42,"country":43,"countryCode":44,"cosmosGeoPoint":45,"geoPoint":50,"contacts":51},"Montevideo","Montevideo Department","11600","Uruguay","UY",{"type":46,"coordinates":47},"Point",[48,49],-56.18816,-34.90328,{"lat":49,"lon":48},[52,55],{"name":29,"role":30,"phone":53,"phoneExt":21,"email":54},"+59824875201","cencar@hc.edu.uy",{"name":35,"role":30,"phone":53,"phoneExt":21,"email":54},{"type":57,"investigatorFullName":58,"investigatorTitle":59,"investigatorAffiliation":5,"oldNameTitle":21,"oldOrganization":21},"PRINCIPAL_INVESTIGATOR","Rafael Mila","Associate Professor of Cardiology and Head of Interventional Cardiology","100639304","invasive-evaluation-and-phenotype-guided-treatment-of-anoca-in-women-100639304",false,"NCT07593157","Invasive Evaluation and Phenotype-Guided Treatment of ANOCA in Women","Invasive Functional and Morphological Coronary Assessment Followed by Phenotype-Guided Multidisciplinary Treatment in Women With Angina and Non-Obstructive Coronary Arteries: A Prospective Single-Center Interventional Study","ANOCA-UY","Inclusion Criteria:\n\n* Female participants aged 35 to 75 years.\n* Symptoms compatible with stable angina or suspected myocardial ischemia.\n* Non-obstructive coronary arteries, defined as absence of angiographic stenosis greater than or equal to 50%.\n* Ability to undergo invasive coronary assessment and clinical follow-up.\n* Written informed consent.\n\nExclusion Criteria:\n\n* Significant structural heart disease.\n* Severe left ventricular systolic dysfunction, defined as left ventricular ejection fraction \\\u003C40%.\n* Clinically relevant contraindication to adenosine or acetylcholine, including severe asthma, untreated high-grade atrioventricular block, or known hypersensitivity.\n* Active oncological disease or life expectancy less than 12 months.\n* Inability to complete the diagnostic or therapeutic study protocol.\n* Participation in another clinical study that could interfere with the present protocol.","FEMALE","35 Years","75 Years",{"count":72,"type":73},50,"ESTIMATED","INTERVENTIONAL",[76],"NA","This prospective single-center interventional study will include women with angina and non-obstructive coronary arteries. Participants will undergo a standardized invasive coronary assessment combining coronary physiology, acetylcholine provocation testing, and optical coherence tomography. The diagnostic protocol will identify functional and morphological mechanisms of angina, including microvascular dysfunction, epicardial vasospasm, microvascular spasm, endothelial dysfunction, functional epicardial disease, combined mechanisms, or normal coronary physiology.\n\nBased on the identified phenotype, participants will receive individualized multidisciplinary treatment, including targeted pharmacological therapy, adapted cardiovascular rehabilitation, and psycho-emotional support when indicated. Clinical follow-up will be performed at 1, 6, and 12 months to assess angina symptoms, quality of life, functional capacity, adherence to treatment, and cardiovascular events.",[79,80,81],"ANOCA - Angina With Non-obstructive Coronary Arteries","Coronary Microvascular Dysfunction (CMD)","Vasospastic Angina",[83,84,85,86,87],"Angina with non-obstructive coronary arteries","ANOCA","INOCA","Vasospastic angina","Coronary Microvascular Dysfunction","NOT_YET_RECRUITING","2026-05-15",{"date":91,"type":92},"2026-05-18","ACTUAL",{"date":89,"type":73},{"date":95,"type":73},"2029-04-30",{"name":5,"class":6},1]